Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluation of efalizumab using safe psoriasis control.

Kim A Papp1, Eric Henninger

  • 1Probity Medical Research, 135 Union Street East, Waterloo, Ontario, Canada. kapapp@probitymedical.com

BMC Dermatology
|September 21, 2006
PubMed
Summary

Efalizumab demonstrates a favorable benefit:risk profile for moderate-to-severe plaque psoriasis treatment. The Safe Psoriasis Control (SPC) measure showed significant improvements in patients receiving efalizumab compared to placebo.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials.

Dermatology and therapy·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

American journal of clinical dermatology·2026
Same author

Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.

Expert opinion on investigational drugs·2026
Same author

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.

PloS one·2026

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Trials

Background:

  • Safe Psoriasis Control (SPC) is a validated comprehensive measure for assessing psoriasis treatment benefit:risk.
  • It integrates efficacy, quality of life, and safety data.
  • Efalizumab is a biologic agent for moderate-to-severe plaque psoriasis.

Purpose of the Study:

  • To assess the benefit:risk profile of efalizumab in moderate-to-severe plaque psoriasis.
  • To apply the Safe Psoriasis Control (SPC) measure to clinical trial data.
  • To evaluate efalizumab's efficacy and safety using a comprehensive outcome.

Main Methods:

  • Utilized week 12 data from four randomized, placebo-controlled Phase III studies.
  • Applied the Safe Psoriasis Control (SPC) measure.

Related Experiment Videos

  • Included retrospective analyses and a prospective analysis with a high-need patient cohort.

    • Main Results:

    • In retrospective analyses, 39.4% of patients on efalizumab achieved SPC versus 10.4% on placebo.
    • In prospective analyses, 34.3% on efalizumab achieved SPC versus 7.3% on placebo.
    • Among high-need patients, 33.0% achieved SPC with efalizumab compared to 3.4% with placebo.

    Conclusions:

    • Efalizumab demonstrates a favorable benefit:risk profile for moderate-to-severe plaque psoriasis.
    • The Safe Psoriasis Control (SPC) measure supports efalizumab's efficacy and safety.
    • Efalizumab offers a beneficial treatment option, particularly for high-need patients.